气候变化领域集成服务门户(CCPortal): REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

CCPortal

DOI	10.1126/science.abe2402
	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
	Baum A.; Ajithdoss D.; Copin R.; Zhou A.; Lanza K.; Negron N.; Ni M.; Wei Y.; Mohammadi K.; Musser B.; Atwal G.S.; Oyejide A.; Goez-Gazi Y.; Dutton J.; Clemmons E.; Staples H.M.; Bartley C.; Klaffke B.; Alfson K.; Gazi M.; Gonzalez O.; Dick E.; Jr.; Carrion R.; Jr.; Pessaint L.; Porto M.; Cook A.; Brown R.; Ali V.; Greenhouse J.; Taylor T.; Andersen H.; Lewis M.G.; Stahl N.; Murphy A.J.; Yancopoulos G.D.; Kyratsous C.A.
发表日期	2020
ISSN	0036-8075
起始页码	1110
结束页码	1115
卷号	370 期号:6520
英文摘要	An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model mild disease, and golden hamsters, which may model more severe disease. We demonstrate that REGN-COV-2 can greatly reduce virus load in the lower and upper airways and decrease virus-induced pathological sequelae when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pneumonia in the lungs. Our results provide evidence of the therapeutic potential of this antibody cocktail. © 2020 American Association for the Advancement of Science. All rights reserved.
英文关键词	anticoronavirus agent; regn cov2; unclassified drug; monoclonal antibody; neutralizing antibody; REGN-COV-2; antibody; induced response; infectious disease; pneumonia; primate; severe acute respiratory syndrome; viral disease; animal experiment; animal tissue; Article; controlled study; coronavirus disease 2019; drug efficacy; in vivo study; infection prevention; nonhuman; priority journal; rhesus monkey; Syrian hamster; virus load; animal; drug combination; Mesocricetus; prevention and control; therapy; Coronavirus; Cricetinae; Macaca mulatta; Mesocricetus auratus; SARS coronavirus; Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; COVID-19; Drug Combinations; Macaca mulatta; Mesocricetus
语种	英语
来源期刊	Science
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/242990
作者单位	Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, United States; Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78245, United States; BIOQUAL, Rockville, MD 20850, United States
推荐引用方式 GB/T 7714	Baum A.,Ajithdoss D.,Copin R.,et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters[J],2020,370(6520).
APA	Baum A..,Ajithdoss D..,Copin R..,Zhou A..,Lanza K..,...&Kyratsous C.A..(2020).REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.Science,370(6520).
MLA	Baum A.,et al."REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters".Science 370.6520(2020).